Observations placeholder
Saphris
Identifier
020021
Type of Spiritual Experience
Background
A description of the experience
senapine (USAN, rINNM and BANM trade names Saphris (AU, US, RU), Sycrest (EU, UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder . Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA approved the manufacturer's NDA in August 2009
It was chemically derived via altering the chemical structure of the tetracyclic (atypical) antidepressant, mianserin.
Adverse effects
Adverse effect incidence
Note: The discussion below these lists provides some more context into the frequency and severity of these adverse effects.
Very common (>10% incidence) adverse effects include:
- Somnolence
Common (1-10% incidence) adverse effects include:
- Weight gain
- Increased appetite
- Extrapyramidal side effects (EPS; such as dystonia, akathisia, dyskinesia, muscle rigidity, parkinsonism)
- Sedation
- Dizziness
- Dysgeusia
- Oral hypoaesthesia
- Increased alanine aminotransferase
- Fatigue
Uncommon (0.1-1% incidence) adverse effects include:
- Hyperglycaemia — elevated blood glucose (sugar)
- Syncope
- Seizure
- Dysarthria
- Sinus bradycardia
- Bundle branch block
- QTc interval prolongation (has a relatively risk for causing QTc interval prolongation)
- Sinus tachycardia
- Orthostatic hypotension
- Hypotension
- Swollen tongue
- Dysphagia (difficulty swallowing)
- Glossodynia
- Oral paraesthesia
Rare (0.01-0.1% incidence) adverse effects include:
- Neuroleptic malignant syndrome (Combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness, and sudden change in blood pressure and heart rate)
- Tardive dyskinesia
- Speech disturbance
- Rhabdomyolysis
- Angioedema
- Blood dyscrasias such as agranulocytosis, leukopenia and neutropenia
On Dec, 31, 2016 6,204 people reported to have side effects when taking Saphris.
Among them, 47 people (0.76%) have Hallucination
Time on Saphris when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 85.71% | 14.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Saphris :
| Female | Male | |
| Hallucination | 36.84% | 63.16% |
Age of people who have Hallucination when taking Saphris :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 5.71% | 5.71% | 8.57% | 8.57% | 45.71% | 25.71% |
On Feb, 3, 2016: 3,984 people reported to have side effects when taking Saphris. Among them, 48 people (1.20%) have Death.
Time on Saphris when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Saphris :
| Female | Male | |
| Death | 57.89% | 42.11% |
Age of people who have Death when taking Saphris :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 10.00% | 40.00% | 40.00% | 10.00% | 0.00% |